Professional Summary
Specializing In
Practice Locations
Patient Ratings
Referring Physicians
Biography
Kavita Sarin, M.D./Ph.D., is an Associate Professor of Dermatology and is the Director of the Stanford Skin Cancer Genetics Program at the Stanford Cancer Institute. She has an academic interest in Precision Medicine, focused on the integration of genetic and clinical patient data to inform susceptibility, prognosis, and treatments in skin cancer and other rare dermatologic disorders. Her lab applies cutting-edge sequencing and imaging technologies to better understand skin cancer and rare immunologic skin diseases. She sees patients in medical dermatology at Portola Valley and the Stanford Cancer Institute
View Full Biography
Professional Summary
Education & Certifications
- Internship: Santa Clara Valley Medical Center Dept of Medicine (2009) CA
- Residency: Stanford University Dept of Dermatology (2012) CA
- Board Certification: American Board of Dermatology, Dermatology (2012)
- Medical Education: Stanford University Medical Center (2008) CA
- PhD, Stanford University- Dept of Genetics, CA (2006)
- BS, Stanford University- Computer Science, CA (2000)
Honors & Awards
- Damon Runyon Clinical Investigator Award, Damon Runyon (2019-2022)
- Department of Dermatology Letter of Teaching Distinction, Stanford University (2019-2020)
- F32 NRSA Ruth L. Kirschstein National Research Service Award, National Institutes of Health (2013-2014)
- Franklin G. Ebaugh, Jr. Award for Excellence in Advising Medical Students, Stanford University School of Medicine (2024)
- K23 NCI Career Development Award, National Institutes of Health (2017-2022)
- Medical Dermatology Career Development Award, Dermatology Foundation (2014-2017)
- Medical Scientist Training Program Scholarship, National Institutes of Health (2000-2008)
- President's Scholar, Stanford University (1996-2000)
- Translational Research and Medicine Award, Stanford University (2013-2014)
- Unsung Hero Award, NBC (1996)
Memberships
- Member, Stanford Center for Population Health Sciences (2015 - Present)
- Member, Stanford Cancer Institute (2015 - Present)
- Member, American Society for Human Genetics (2019 - Present)
- Member, Children's Health Research Institute (2017 - Present)
- Fellow, American Academy of Dermatology (2009 - Present)
- Member, Society of Investigative Dermatology (2014 - Present)
Publications
-
Conditional telomerase induction causes proliferation of hair follicle stem cells
Sarin, K. Y., Cheung, P., Gilison, D., Lee, E., Tennen, R. I., Wang, E., … Artandi, S. E. (2005). Conditional telomerase induction causes proliferation of hair follicle stem cells. NATURE, 436(7053), 1048–52. -
Aging, graying and loss of melanocyte stem cells
Sarin, K. Y., & Artandi, S. E. (2007). Aging, graying and loss of melanocyte stem cells. STEM CELL REVIEWS, 3(3), 212–17. -
TERT promotes epithelial proliferation through transcriptional control of a Myc- and Wnt-related developmental program
Choi, J., Southworth, L. K., Sarin, K. Y., Venteicher, A. S., Ma, W., Chang, W., … Artandi, S. E. (2008). TERT promotes epithelial proliferation through transcriptional control of a Myc- and Wnt-related developmental program. PLOS GENETICS, 4(1). -
Reversible cell-cycle entry in adult kidney podocytes through regulated control of telomerase and Wnt signaling.
Shkreli, M., Sarin, K. Y., Pech, M. F., Papeta, N., Chang, W., Brockman, S. A., … Artandi, S. E. (2012). Reversible cell-cycle entry in adult kidney podocytes through regulated control of telomerase and Wnt signaling. Nature Medicine, 18(1), 111–119. -
Treatment of Recalcitrant Eosinophilic Cellulitis With Adalimumab
Sarin, K. Y., & Fiorentino, D. (2012). Treatment of Recalcitrant Eosinophilic Cellulitis With Adalimumab. ARCHIVES OF DERMATOLOGY, 148(9), 990–92. -
Mosaic Activating RAS Mutations in Nevus Sebaceus and Nevus Sebaceus Syndrome
Sun, B. K., Saggini, A., Sarin, K. Y., Kim, J., Benjamin, L., LeBoit, P. E., & Khavari, P. A. (2013). Mosaic Activating RAS Mutations in Nevus Sebaceus and Nevus Sebaceus Syndrome. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 133(3), 824–27. -
Activating HRAS mutation in agminated Spitz nevi arising in a nevus spilus.
Sarin, K. Y., Sun, B. K., Bangs, C. D., Cherry, A., Swetter, S. M., Kim, J., & Khavari, P. A. (2013). Activating HRAS mutation in agminated Spitz nevi arising in a nevus spilus. JAMA Dermatology , 149(9), 1077–81. -
Dermatomyositis associated with capecitabine in the setting of malignancy.
Chen, F. W., Zhou, X., Egbert, B. M., Swetter, S. M., & Sarin, K. Y. (2014). Dermatomyositis associated with capecitabine in the setting of malignancy. Journal of the American Academy of Dermatology, 70(2), e47–8. -
Activating HRAS Mutation in Nevus Spilus.
Sarin, K. Y., McNiff, J. M., Kwok, S., Kim, J., & Khavari, P. A. (2014). Activating HRAS Mutation in Nevus Spilus. Journal of Investigative Dermatology, 134(6), 1766–68. -
Dermatomyositis associated with capecitabine in the setting of malignancy
Chen, F. W., Zhou, X., Egbert, B. M., Swetter, S. M., & Sarin, K. Y. (2014). Dermatomyositis associated with capecitabine in the setting of malignancy. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 70(2), E47–E48. -
Smoothened variants explain the majority of drug resistance in Basal cell carcinoma.
Atwood, S. X., Sarin, K. Y., Whitson, R. J., Li, J. R., Kim, G., Rezaee, M., … Tang, J. Y. (2015). Smoothened variants explain the majority of drug resistance in Basal cell carcinoma. Cancer Cell, 27(3), 342–53. -
Genomic analysis of smoothened inhibitor resistance in Basal cell carcinoma.
Sharpe, H. J., Pau, G., Dijkgraaf, G. J., Basset-Seguin, N., Modrusan, Z., Januario, T., … de Sauvage, F. J. (2015). Genomic analysis of smoothened inhibitor resistance in Basal cell carcinoma. Cancer Cell, 27(3), 327–41. -
Rolling the Genetic Dice: Neutral and Deleterious Smoothened Mutations in Drug-Resistant Basal Cell Carcinoma.
Atwood, S. X., Sarin, K. Y., Li, J. R., Yao, C. Y., Urman, N. M., Chang, A. L. S., … Oro, A. E. (2015). Rolling the Genetic Dice: Neutral and Deleterious Smoothened Mutations in Drug-Resistant Basal Cell Carcinoma. Journal of Investigative Dermatology, 135(8), 2138–41. -
Dermatologic applications of direct-to-consumer genomic analysis.
Fogel, A. L., Azizi, N., Tang, J., & Sarin, K. Y. (2014). Dermatologic applications of direct-to-consumer genomic analysis. Journal of the American Academy of Dermatology, 71(5), 993–95. -
A subdermal source: contact dermatitis.
Fogel, A. L., Longmire, M., Rieger, K. E., & Sarin, K. Y. (2015). A subdermal source: contact dermatitis. American Journal of Medicine, 128(6), 578–81. -
Molecular Profiling to Diagnose a Case of Atypical Dermatomyocitis
Sarin, K., Chung, L., Kim, J., Higgs, B. W., Jallal, B., Yao, Y., & Fiorentino, D. (2013). Molecular Profiling to Diagnose a Case of Atypical Dermatomyocitis. Journal of Investigative Dermatology, 133(12). -
Squamous Change in Basal-Cell Carcinoma with Drug Resistance.
Ransohoff, K. J., Tang, J. Y., & Sarin, K. Y. (2015). Squamous Change in Basal-Cell Carcinoma with Drug Resistance. New England Journal of Medicine, 373(11), 1079–82. -
Mutations in the Kinetochore Gene KNSTRN in Basal Cell Carcinoma.
Jaju, P. D., Nguyen, C. B., Mah, A. M., Atwood, S. X., Li, J., Zia, A., … Sarin, K. Y. (2015). Mutations in the Kinetochore Gene KNSTRN in Basal Cell Carcinoma. Journal of Investigative Dermatology, 135(12), 3197–3200. -
Smoothened Inhibitors in Sonic Hedgehog Subgroup Medulloblastoma.
Ransohoff, K. J., Sarin, K. Y., & Tang, J. Y. (2015). Smoothened Inhibitors in Sonic Hedgehog Subgroup Medulloblastoma. Journal of Clinical Oncology , 33(24), 2692–94. -
Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma.
Ally, M. S., Ransohoff, K., Sarin, K., Atwood, S. X., Rezaee, M., Bailey-Healy, I., … Colevas, A. D. (2016). Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma. JAMA Dermatology, 152(4), 452–56. -
Squamous Change in Basal-Cell Carcinoma with Drug Resistance
Ransohoff, K. J., Tang, J. Y., & Sarin, K. Y. (2015). Squamous Change in Basal-Cell Carcinoma with Drug Resistance. NEW ENGLAND JOURNAL OF MEDICINE, 373(11), 1079–82. -
Familial skin cancer syndromes: Increased risk of nonmelanotic skin cancers and extracutaneous tumors
Sarin, K. Y., Tang, J. Y., Ransohoff, K. J., & Jaju, P. D. (2016). Familial skin cancer syndromes: Increased risk of nonmelanotic skin cancers and extracutaneous tumors. Journal of The American Academy of Dermatology, 74(3). -
Familial skin cancer syndromes: Increased melanoma risk
Jaju, P. D., Ransohoff, K. J., Tang, J. Y., & Sarin, K. Y. (2016). Familial skin cancer syndromes: Increased melanoma risk. Journal of The American Academy of Dermatology, 74(3). -
Effects of combined treatment with arsenic trioxide and itraconazole in patients with refractory metastatic basal cell carcinoma
Sarin, K. Y., Ally, M. S., Ransohoff, K. J., Atwood, S. X., & Rezaee, M. (2016). Effects of combined treatment with arsenic trioxide and itraconazole in patients with refractory metastatic basal cell carcinoma. JAMA Dermatology, 1–5. -
An investigator-initiated open label trial of sonidegib in advanced basal cell carcinoma patients resistant to vismodegib
Sarin, K. Y., Oro, A. E., Chang, A. L., & Danial, C. (2015). An investigator-initiated open label trial of sonidegib in advanced basal cell carcinoma patients resistant to vismodegib. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. -
A survey of direct-to-consumer teledermatology services available to US patients: Explosive growth, opportunities, and controversy
Fogel, A. L., & Sarin, K. Y. (2016). A survey of direct-to-consumer teledermatology services available to US patients: Explosive growth, opportunities, and controversy. Journal of Telemedicine and Telecare, (January). -
The digital age of melanoma management: detection and diagnostics
Fogel, A. L., & Sarin, K. Y. (2015). The digital age of melanoma management: detection and diagnostics. Future Medicine, 2(4), 383–391. -
Familial skin cancer syndromes Increased melanoma risk
Ransohoff, K. J., Jaju, P. D., Tang, J. Y., Carbone, M., Leachman, S., & Sarin, K. Y. (2016). Familial skin cancer syndromes Increased melanoma risk. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 74(3), 423–34. -
Familial skin cancer syndromes Increased risk of nonmelanotic skin cancers and extracutaneous tumors
Jaju, P. D., Ransohoff, K. J., Tang, J. Y., & Sarin, K. Y. (2016). Familial skin cancer syndromes Increased risk of nonmelanotic skin cancers and extracutaneous tumors. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 74(3), 437–51. -
An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib
Danial, C., Sarin, K. Y., Oro, A. E., & Chang, A. L. S. (2016). An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib. CLINICAL CANCER RESEARCH, 22(6), 1325–29. -
Assessment of Accuracy of Patient-Initiated Differential Diagnosis Generation by Google Reverse Image Searching.
Ransohoff, J. D., Li, S., & Sarin, K. Y. (2016). Assessment of Accuracy of Patient-Initiated Differential Diagnosis Generation by Google Reverse Image Searching. JAMA Dermatology, 152(10), 1164–66. -
Genome-wide association study identifies 14 novel risk alleles associated with basal cell carcinoma.
Chahal, H. S., Wu, W., Ransohoff, K. J., Yang, L., Hedlin, H., Desai, M., … Sarin, K. Y. (2016). Genome-wide association study identifies 14 novel risk alleles associated with basal cell carcinoma. Nature Communications, 7, 12510-? -
Identification of Alpha-Adrenergic Agonists as Potential Therapeutic Agents for Dermatomyositis through Drug-Repurposing Using Public Expression Datasets.
Cho, H. G., Fiorentino, D., Lewis, M., Sirota, M., & Sarin, K. Y. (2016). Identification of Alpha-Adrenergic Agonists as Potential Therapeutic Agents for Dermatomyositis through Drug-Repurposing Using Public Expression Datasets. Journal of Investigative Dermatology, 136(7), 1517–20. -
Genome-wide association study identifies novel susceptibility loci for cutaneous squamous cell carcinoma.
Chahal, H. S., Lin, Y., Ransohoff, K. J., Hinds, D. A., Wu, W., Dai, H.-ji, … Sarin, K. Y. (2016). Genome-wide association study identifies novel susceptibility loci for cutaneous squamous cell carcinoma. Nature Communications, 7, 12048-? -
Reversible cell-cycle entry in adult kidney podocytes through regulated control of telomerase and Wnt signaling
Shkreli, M., Sarin, K. Y., Pech, M. F., Papeta, N., Chang, W., Brockman, S. A., … Artandi, S. E. (2012). Reversible cell-cycle entry in adult kidney podocytes through regulated control of telomerase and Wnt signaling. NATURE MEDICINE, 18(1), 111–19. -
Invasive Melanoma in a Patient with Congenital Ichthyosiform Erythroderma.
Jaju, P., Novoa, R. A., Swetter, S. M., & Sarin, K. Y. (2016). Invasive Melanoma in a Patient with Congenital Ichthyosiform Erythroderma. Pediatric Dermatology. -
Direct-to-consumer teledermatology services for pediatric patients: Room for improvement.
Fogel, A. L., Teng, J., & Sarin, K. Y. (2016). Direct-to-consumer teledermatology services for pediatric patients: Room for improvement. Journal of the American Academy of Dermatology, 75(5), 887–88. -
Tumor-Derived Suppressor of Fused Mutations Reveal Hedgehog Pathway Interactions
Urman, N. M., Mirza, A., Atwood, S. X., Whitson, R. J., Sarin, K. Y., Tang, J. Y., & Oro, A. E. (2016). Tumor-Derived Suppressor of Fused Mutations Reveal Hedgehog Pathway Interactions. PLOS ONE, 11(12). -
Factors influencing and modifying the decision to pursue genetic testing for skin cancer risk.
Fogel, A. L., Jaju, P. D., Li, S., Halpern-Felsher, B., Tang, J. Y., & Sarin, K. Y. (2017). Factors influencing and modifying the decision to pursue genetic testing for skin cancer risk. Journal of the American Academy of Dermatology. -
Incidence ratio of basal cell carcinoma to squamous cell carcinoma equalizes with age.
Chahal, H. S., Rieger, K. E., & Sarin, K. Y. (2017). Incidence ratio of basal cell carcinoma to squamous cell carcinoma equalizes with age. Journal of the American Academy of Dermatology, 76(2), 353–54. -
Association between genetic variation within vitamin D receptor-DNA binding sites and risk of basal cell carcinoma.
Lin, Y., Chahal, H. S., Wu, W., Cho, H. G., Ransohoff, K. J., Dai, H., … Han, J. (2017). Association between genetic variation within vitamin D receptor-DNA binding sites and risk of basal cell carcinoma. International Journal of Cancer. -
A survey of direct-to-consumer teledermatology services available to US patients: Explosive growth, opportunities and controversy.
Fogel, A. L., & Sarin, K. Y. (2017). A survey of direct-to-consumer teledermatology services available to US patients: Explosive growth, opportunities and controversy. Journal of Telemedicine and Telecare, 23(1), 19–25. -
Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma.
Ransohoff, K. J., Wu, W., Cho, H. G., Chahal, H. C., Lin, Y., Dai, H.-ji, … Sarin, K. Y. (2017). Two-stage genome-wide association study identifies a novel susceptibility locus associated with melanoma. Oncotarget. -
Basosquamous Carcinoma: Controversy, Advances, and Future Directions.
Tan, C. Z., Rieger, K. E., & Sarin, K. Y. (2017). Basosquamous Carcinoma: Controversy, Advances, and Future Directions. Dermatologic Surgery , 43(1), 23–31. -
Invasive Melanoma in a Patient with Congenital Ichthyosiform Erythroderma
Jaju, P., Novoa, R. A., Swetter, S. M., & Sarin, K. Y. (2017). Invasive Melanoma in a Patient with Congenital Ichthyosiform Erythroderma. PEDIATRIC DERMATOLOGY, 34(1), E35–E36. -
Association study of genetic variation in DNA repair pathway genes and risk of basal cell carcinoma.
Lin, Y., Chahal, H. S., Wu, W., Cho, H. G., Ransohoff, K. J., Song, F., … Han, J. (2017). Association study of genetic variation in DNA repair pathway genes and risk of basal cell carcinoma. International Journal of Cancer. -
Genetic diseases associated with an increased risk of skin cancer development in childhood.
Fogel, A. L., Sarin, K. Y., & Teng, J. M. C. (2017). Genetic diseases associated with an increased risk of skin cancer development in childhood. Current Opinion in Pediatrics. -
Postzygotic Mutations in Beta-Actin are Associated with Becker's Nevus and Becker's Nevus Syndrome.
Cai, E. D., Sun, B. K., Chiang, A., Rogers, A., Bernet, L., Cheng, B., … Sarin, K. Y. (2017). Postzygotic Mutations in Beta-Actin are Associated with Becker's Nevus and Becker's Nevus Syndrome. Journal of Investigative Dermatology. -
Correlates of multiple basal cell carcinoma in a retrospective cohort study: Sex, histologic subtypes, and anatomic distribution.
Kuo, K. Y., Batra, P., Cho, H. G., Li, S., Chahal, H. S., Rieger, K. E., … Sarin, K. Y. (2017). Correlates of multiple basal cell carcinoma in a retrospective cohort study: Sex, histologic subtypes, and anatomic distribution. Journal of the American Academy of Dermatology. -
IFN?-Dependent Tissue-Immune Homeostasis Is Co-opted in the Tumor Microenvironment.
Nirschl, C. J., Suárez-Fariñas, M., Izar, B., Prakadan, S., Dannenfelser, R., Tirosh, I., … Anandasabapathy, N. (2017). IFN?-Dependent Tissue-Immune Homeostasis Is Co-opted in the Tumor Microenvironment. Cell, 170(1), 127–41.e15. -
Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment.
Mirza, A. N., Fry, M. A., Urman, N. M., Atwood, S. X., Roffey, J., Ott, G. R., … Oro, A. E. (2017). Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment. JCI Insight, 2(21). -
Genomic Stability in Syndromic Basal Cell Carcinoma.
Chiang, A., Jaju, P. D., Batra, P., Rezaee, M., Epstein, E. H., Tang, J. Y., & Sarin, K. Y. (2017). Genomic Stability in Syndromic Basal Cell Carcinoma. The Journal of Investigative Dermatology. -
Noncanonical hedgehog pathway activation through SRF-MKL1 promotes drug resistance in basal cell carcinomas.
Whitson, R. J., Lee, A., Urman, N. M., Mirza, A., Yao, C. Y., Brown, A. S., … Oro, A. E. (2018). Noncanonical hedgehog pathway activation through SRF-MKL1 promotes drug resistance in basal cell carcinomas. Nature Medicine, 24(3), 271–81. -
Activity of Type I and Type II Interferons in Dermatomyositis Skin Is Correlated with Characteristic Pathologic Features
Leatham, H. W., Rieger, K., Chung, L., Li, S., Higgs, B. W., Yao, Y., … Fiorentino, D. (2015). Activity of Type I and Type II Interferons in Dermatomyositis Skin Is Correlated with Characteristic Pathologic Features. ARTHRITIS & RHEUMATOLOGY, 67. -
Detecting Chemotherapeutic Skin Adverse Reactions in Social Health Networks Using Deep Learning.
Ransohoff, J. D., Nikfarjam, A., Jones, E., Loew, B., Kwong, B. Y., Sarin, K. Y., & Shah, N. H. (2018). Detecting Chemotherapeutic Skin Adverse Reactions in Social Health Networks Using Deep Learning. JAMA Oncology, 4(4), 581–83. -
Melanoma risk prediction using a multilocus genetic risk score in the Women's Health Initiative cohort.
Cho, H. G., Ransohoff, K. J., Yang, L., Hedlin, H., Assimes, T., Han, J., … Sarin, K. Y. (2018). Melanoma risk prediction using a multilocus genetic risk score in the Women's Health Initiative cohort. Journal of the American Academy of Dermatology. -
Azathioprine and risk of multiple keratinocyte cancers.
Cho, H. G., Kuo, K. Y., Xiao, K., Batra, P., Li, S., Tang, J. Y., & Sarin, K. Y. (2018). Azathioprine and risk of multiple keratinocyte cancers. Journal of the American Academy of Dermatology, 78(1), 27–28.e1. -
TGF-beta, Fibronectin and Integrin alpha5beta1 Promote Invasion in Basal Cell Carcinoma.
Kuonen, F., Surbeck, I., Sarin, K. Y., Dontenwill, M., Ruegg, C., Gilliet, M., … Gaide, O. (2018). TGF-beta, Fibronectin and Integrin alpha5beta1 Promote Invasion in Basal Cell Carcinoma. The Journal of Investigative Dermatology. -
Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes
Ko, J. S., Matharoo-Ball, B., Billings, S. D., Thomson, B. J., Tang, J. Y., Sarin, K. Y., … Clarke, L. E. (2017). Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 26(7), 1107–13. -
Identification of Atorvastatin for Moderate to Severe Hidradenitis through Drug Repositioning Using Public Gene Expression Datasets
Kuo, K. Y., Cho, H. G., & Sarin, K. Y. (2018). Identification of Atorvastatin for Moderate to Severe Hidradenitis through Drug Repositioning Using Public Gene Expression Datasets. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 138(5), 1209–12. -
Frequent basal cell cancer development is a clinical marker for inherited cancer susceptibility
Cho, H. G., Kuo, K. Y., Li, S., Bailey, I., Aasi, S., Chang, A. L. S., … Sarin, K. Y. (2018). Frequent basal cell cancer development is a clinical marker for inherited cancer susceptibility. JCI INSIGHT, 3(15). -
Pembrolizumab for advanced basal cell carcinoma: an investigator-initiated, proof-of-concept study.
Chang, A. L., Tran, D. C., Cannon, J. G., Li, S., Jeng, M., Patel, R., … Colevas, A. D. (2018). Pembrolizumab for advanced basal cell carcinoma: an investigator-initiated, proof-of-concept study. Journal of the American Academy of Dermatology. -
Inverse Relationship between Vitiligo-Related Genes and Skin Cancer Risk
Wu, W., Amos, C. I., Lee, J. E., Wei, Q., Sarin, K. Y., & Han, J. (2018). Inverse Relationship between Vitiligo-Related Genes and Skin Cancer Risk. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 138(9), 2072–75. -
Automated Classification of Skin Lesions: From Pixels to Practice.
Narla, A., Kuprel, B., Sarin, K., Novoa, R., & Ko, J. (2018). Automated Classification of Skin Lesions: From Pixels to Practice. The Journal of Investigative Dermatology, 138(10), 2108–10. -
Association of multiple primary melanomas with malignancy risk: a population-based analysis of the Surveillance, Epidemiology, and End Results Program database from 1973-2014.
Cai, E. D., Swetter, S. M., & Sarin, K. Y. (2018). Association of multiple primary melanomas with malignancy risk: a population-based analysis of the Surveillance, Epidemiology, and End Results Program database from 1973-2014. Journal of the American Academy of Dermatology. -
A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations.
Pastorino, S., Yoshikawa, Y., Pass, H. I., Emi, M., Nasu, M., Pagano, I., … Carbone, M. (2018). A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2018790352. -
Biomarker discovery analysis: Alterations in p14, p16, p53, and BAP1 expression in nevi, cutaneous melanoma, and metastatic melanoma.
Sargen, M. R., Cloutier, J. M., Sarin, K. Y., Rieger, K. E., Chu, P., Swetter, S. M., & Novoa, R. A. (2019). Biomarker discovery analysis: Alterations in p14, p16, p53, and BAP1 expression in nevi, cutaneous melanoma, and metastatic melanoma. Pigment Cell & Melanoma Research. -
Loss of primary cilia drives switching from Hedgehog to Ras/MAPK pathway in resistant basal cell carcinoma.
Kuonen, F., Huskey, N. E., Shankar, G., Jaju, P., Whitson, R. J., Rieger, K. E., … Oro, A. E. (2019). Loss of primary cilia drives switching from Hedgehog to Ras/MAPK pathway in resistant basal cell carcinoma. The Journal of Investigative Dermatology. -
Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes
Ko, J., Matharoo-Ball, B., Billings, S., Thomson, B., Tang, J., Sarin, K., … Clarke, L. (2017). Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes. MODERN PATHOLOGY. NATURE PUBLISHING GROUP. -
Dermatologic applications of direct-to-consumer genomic analysis
Fogel, A., Tang, J., Sarin, K., & Azizi, N. (2014). Dermatologic applications of direct-to-consumer genomic analysis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 70(5), AB80. -
Alterations of the MEK/ERK, BMP, and Wnt/beta-catenin pathways detected in the blood of individuals with lymphatic malformations.
Kim, T., Tafoya, E., Chelliah, M. P., Lekwuttikarn, R., Li, J., Sarin, K. Y., & Teng, J. (2019). Alterations of the MEK/ERK, BMP, and Wnt/beta-catenin pathways detected in the blood of individuals with lymphatic malformations. PloS One, 14(4), e0213872. -
The digital age of melanoma management: detection and diagnostics.
Fogel, A. L., & Sarin, K. (2015). The digital age of melanoma management: detection and diagnostics. Melanoma Management, 2(4), 383–391. -
Alterations of the MEK/ERK, BMP, and Wnt/beta-catenin pathways detected in the blood of individuals with lymphatic malformations
Kim, T., Tafoya, E., Chelliah, M. P., Lekwuttikarn, R., Li, J., Sarin, K. Y., & Teng, J. (2019). Alterations of the MEK/ERK, BMP, and Wnt/beta-catenin pathways detected in the blood of individuals with lymphatic malformations. PLOS ONE, 14(4). -
Emerging technologies for health information in dermatology: opportunities and drawbacks of web-based searches, social media, mobile applications, and direct-to-consumer genetic testing in patient care.
Jia, J. L., Polin, D. J., & Sarin, K. Y. (2019). Emerging technologies for health information in dermatology: opportunities and drawbacks of web-based searches, social media, mobile applications, and direct-to-consumer genetic testing in patient care. Seminars in Cutaneous Medicine and Surgery, 38(1), E57–E53. -
Biomarker discovery analysis: Alterations in p14, p16, p53, and BAP1 expression in nevi, cutaneous melanoma, and metastatic melanoma
Sargen, M. R., Cloutier, J. M., Sarin, K. Y., Rieger, K. E., Chu, P., Swetter, S. M., & Novoa, R. A. (2019). Biomarker discovery analysis: Alterations in p14, p16, p53, and BAP1 expression in nevi, cutaneous melanoma, and metastatic melanoma. PIGMENT CELL & MELANOMA RESEARCH, 32(3), 474–78. -
Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study
Chang, A. L. S., Tran, D. C., Cannon, J. G. D., Li, S., Jeng, M., Patel, R., … Colevas, A. D. (2019). Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 80(2), 564–66. -
Early Detection of Adverse Drug Reactions in Social Health Networks: A Natural Language Processing Pipeline for Signal Detection.
Nikfarjam, A., Ransohoff, J. D., Callahan, A., Jones, E., Loew, B., Kwong, B. Y., … Shah, N. H. (2019). Early Detection of Adverse Drug Reactions in Social Health Networks: A Natural Language Processing Pipeline for Signal Detection. JMIR Public Health and Surveillance, 5(2), e11264. -
Melanoma risk prediction using a multilocus genetic risk score in the Women's Health Initiative cohort
Cho, H. G., Ransohoff, K. J., Yang, L., Hedlin, H., Assimes, T., Han, J., … Sarin, K. Y. (2018). Melanoma risk prediction using a multilocus genetic risk score in the Women's Health Initiative cohort. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 79(1), 36-+. -
Genetic Mutations Underlying Phenotypic Plasticity in Basosquamous Carcinoma
Chiang, A., Tan, C. Z., Kuonen, F., Hodgkinson, L. M., Chiang, F., Cho, R. J., … Sarin, K. Y. (2019). Genetic Mutations Underlying Phenotypic Plasticity in Basosquamous Carcinoma. Journal of INVESTIGATIVE DERMATOLOGY | Original Article | Carcinogenesis/Tumorigenesis, 139(11). -
Loss of Primary Cilia Drives Switching from Hedgehog to Ras/MAPK Pathway in Resistant Basal Cell Carcinoma
Kuonen, F., Huskey, N. E., Shankar, G., Jaju, P., Whitson, R. J., Rieger, K. E., … Oro, A. E. (2019). Loss of Primary Cilia Drives Switching from Hedgehog to Ras/MAPK Pathway in Resistant Basal Cell Carcinoma. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 139(7), 1439–48. -
Topical Itraconazole for the Treatment of Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome or High-Frequency Basal Cell Carcinomas: A Phase 2, Open-Label, Placebo-Controlled Trial.
Sohn, G. K., Kwon, G. P., Bailey-Healy, I., Mirza, A., Sarin, K., Oro, A., & Tang, J. Y. (2019). Topical Itraconazole for the Treatment of Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome or High-Frequency Basal Cell Carcinomas: A Phase 2, Open-Label, Placebo-Controlled Trial. JAMA Dermatology. -
Response to Clarifying the Current Understanding of Syndromic Basal Cell Carcinomas.
Chiang, A., Batra, P., & Sarin, K. Y. (2019). Response to Clarifying the Current Understanding of Syndromic Basal Cell Carcinomas. The Journal of Investigative Dermatology. -
Clonal replacement of tumor-specific T cells following PD-1 blockade.
Yost, K. E., Satpathy, A. T., Wells, D. K., Qi, Y., Wang, C., Kageyama, R., … Chang, H. Y. (2019). Clonal replacement of tumor-specific T cells following PD-1 blockade. Nature Medicine. -
Azathioprine and risk of multiple keratinocyte cancers
Cho, H. G., Kuo, K. Y., Xiao, K., Batra, P., Li, S., Tang, J. Y., & Sarin, K. Y. (2018). Azathioprine and risk of multiple keratinocyte cancers. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 78(1), 27-+. -
Unique Tumor Heterogeneity Within a Single Locally Advanced Basal Cell Carcinoma Resulting in a Partial Response Despite Continuous Vismodegib Treatment
Nayyar, P. M., Chang, A. L. S., Sarin, K., & Ratner, D. (2019). Unique Tumor Heterogeneity Within a Single Locally Advanced Basal Cell Carcinoma Resulting in a Partial Response Despite Continuous Vismodegib Treatment. DERMATOLOGIC SURGERY, 45(4), 608–10. -
Hyperhidrosis affects quality of life in hidradenitis suppurativa: a prospective analysis.
Hua, V. J., Kuo, K. Y., Cho, H. G., & Sarin, K. Y. (2019). Hyperhidrosis affects quality of life in hidradenitis suppurativa: a prospective analysis. Journal of the American Academy of Dermatology. -
Assessment of readability and content of patient-initiated google search results for epidermolysis bullosa.
Jia, J. L., Nguyen, B., & Sarin, K. Y. (2019). Assessment of readability and content of patient-initiated google search results for epidermolysis bullosa. Pediatric Dermatology. -
A phase 1b, open-label, investigator-initiated, proof-of-concept study of pembrolizumab for advanced basal cell carcinomas
Chang, A., Duy Tran, Cannon, J., Li, S., Jeng, M., Rieger, K., … Colevas, D. (2019). A phase 1b, open-label, investigator-initiated, proof-of-concept study of pembrolizumab for advanced basal cell carcinomas. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 81(4), AB8. -
Emerging technologies for health information in dermatology: opportunities and drawbacks of web-based searches, social media, mobile applications, and direct-to-consumer genetic testing in patient care
Jia, J. L., Polin, D. J., & Sarin, K. Y. (2019). Emerging technologies for health information in dermatology: opportunities and drawbacks of web-based searches, social media, mobile applications, and direct-to-consumer genetic testing in patient care. SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 38(1), E57–E63. -
Comparing Online Engagement and Academic Impact of Dermatology Research: An Altmetric Attention Score and PlumX Metrics Analysis.
Jia, J. L., Nguyen, B., Mills, D. E., Polin, D. J., & Sarin, K. Y. (2019). Comparing Online Engagement and Academic Impact of Dermatology Research: An Altmetric Attention Score and PlumX Metrics Analysis. Journal of the American Academy of Dermatology. -
From Clinical Phenotype to Genotypic Modelling: Incidence and Prevalence of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Eichstadt, S., Tang, J. Y., Solis, D. C., Siprashvili, Z., Marinkovich, M. P., Whitehead, N., … Sarin, K. Y. (2019). From Clinical Phenotype to Genotypic Modelling: Incidence and Prevalence of Recessive Dystrophic Epidermolysis Bullosa (RDEB). CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 12, 933–42. -
From Clinical Phenotype to Genotypic Modelling: Incidence and Prevalence of Recessive Dystrophic Epidermolysis Bullosa (RDEB).
Eichstadt, S., Tang, J. Y., Solis, D. C., Siprashvili, Z., Marinkovich, M. P., Whitehead, N., … Sarin, K. Y. (2019). From Clinical Phenotype to Genotypic Modelling: Incidence and Prevalence of Recessive Dystrophic Epidermolysis Bullosa (RDEB). Clinical, Cosmetic and Investigational Dermatology, 12, 933–942. -
Angular compounding for speckle reduction in optical coherence tomography using geometric image registration algorithm and digital focusing.
Zhao, J., Winetraub, Y., Yuan, E., Chan, W. H., Aasi, S. Z., Sarin, K. Y., … de la Zerda, A. (2020). Angular compounding for speckle reduction in optical coherence tomography using geometric image registration algorithm and digital focusing. Scientific Reports, 10(1), 1893. -
Genome-wide meta-analysis identifies eight new susceptibility loci for cutaneous squamous cell carcinoma.
Sarin, K. Y., Lin, Y., Daneshjou, R., Ziyatdinov, A., Thorleifsson, G., Rubin, A., … Han, J. (2020). Genome-wide meta-analysis identifies eight new susceptibility loci for cutaneous squamous cell carcinoma. Nature Communications, 11(1), 820. -
Ways to Improve Care for LGBT Patients in Dermatology Clinics.
Jia, J. L., Polin, D. J., & Sarin, K. Y. (2020). Ways to Improve Care for LGBT Patients in Dermatology Clinics. Dermatologic Clinics, 38(2), 269–76. -
Sexual and Gender Minority Curricula Within US Dermatology Residency Programs.
Jia, J. L., Nord, K. M., Sarin, K. Y., Linos, E., & Bailey, E. E. (2020). Sexual and Gender Minority Curricula Within US Dermatology Residency Programs. JAMA Dermatology. -
Gamification improves melanoma visual identification among high school students: Results from a randomized study.
Jia, J. L., Shen, A., Tabata, M. M., & Sarin, K. Y. (2020). Gamification improves melanoma visual identification among high school students: Results from a randomized study. Pediatric Dermatology. -
Fitzpatrick Phototype Disparities in Identification of Cutaneous Malignancies by Google Reverse Image.
Jia, J. L., Wang, J. Y., Mills, D. E., Shen, A., & Sarin, K. Y. (2020). Fitzpatrick Phototype Disparities in Identification of Cutaneous Malignancies by Google Reverse Image. Journal of the American Academy of Dermatology. -
Diagnostic distinction of malignant melanoma and benign nevi by a gene expression signature and correlation to clinical outcomes
Kim, J., Ko, J., Matharoo-Ball, B., Billings, S., Thomson, B., Sarin, K., … Clarke, L. (2017). Diagnostic distinction of malignant melanoma and benign nevi by a gene expression signature and correlation to clinical outcomes. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. MOSBY-ELSEVIER. -
Prevalence and risk factors for high frequency basal cell carcinoma in the United States.
Chiang, A., Solis, D. C., Rogers, H., Sohn, G. K., Cho, H. G., Saldanha, G., … Tang, J. Y. (2020). Prevalence and risk factors for high frequency basal cell carcinoma in the United States. Journal of the American Academy of Dermatology. -
A phase 2 double-blinded, placebo-controlled trial of toll-like receptor 7,8,9 antagonist, IMO-8400, in dermatomyositis.
Kim, Y. J., Schiopu, E., Dankó, K., Mozaffar, T., Chunduru, S., Lees, K., … Sarin, K. Y. (2020). A phase 2 double-blinded, placebo-controlled trial of toll-like receptor 7,8,9 antagonist, IMO-8400, in dermatomyositis. Journal of the American Academy of Dermatology. -
Phenotypic heterogeneity of neurofibromatosis type 1 in a large international registry.
Tabata, M. M., Li, S., Knight, P., Bakker, A., & Sarin, K. Y. (2020). Phenotypic heterogeneity of neurofibromatosis type 1 in a large international registry. JCI Insight, 5(16). -
AP-1 and TGFSS cooperativity drives non-canonical Hedgehog signaling in resistant basal cell carcinoma.
Yao, C. D., Haensel, D., Gaddam, S., Patel, T., Atwood, S. X., Sarin, K. Y., … Oro, A. E. (2020). AP-1 and TGFSS cooperativity drives non-canonical Hedgehog signaling in resistant basal cell carcinoma. Nature Communications, 11(1), 5079. -
Patient Crowdfunding for the Treatment of Cutaneous Malignancies.
Jia, J. L., Mills, D. E., Urman, N. M., & Sarin, K. Y. (2020). Patient Crowdfunding for the Treatment of Cutaneous Malignancies. Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]. -
Crowdfunding for the treatment of cutaneous malignancies: Trends, correlates, and money raised
Jia, J. L., Mills, D., & Sarin, K. Y. (2020). Crowdfunding for the treatment of cutaneous malignancies: Trends, correlates, and money raised. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 83(6), AB107. -
Direct-to-Consumer Genetic Risk Scoring for Melanoma Improves Adherence to Sun-Protective Behaviors Among Increased-Risk Groups: Results from a Prospective U.S. Cohort Study.
Hu, X., Kilgour, J. M., Fogel, A. L., Jia, J. L., Jaju, P. D., Tang, J. Y., & Sarin, K. Y. (2021). Direct-to-Consumer Genetic Risk Scoring for Melanoma Improves Adherence to Sun-Protective Behaviors Among Increased-Risk Groups: Results from a Prospective U.S. Cohort Study. Journal of the American Academy of Dermatology. -
Loss-of-Function Variants in the Tumor Suppressor Gene PTPN14 confer increased Cancer Risk.
Olafsdottir, T., Stacey, S. N., Sveinbjornsson, G., Thorleifsson, G., Norland, K., Sigurgeirsson, B., … Stefansson, K. (2021). Loss-of-Function Variants in the Tumor Suppressor Gene PTPN14 confer increased Cancer Risk. Cancer Research. -
Journal attitudes and outcomes of preprints in dermatology.
Jia, J. L., Hua, V. J., Mills, D. E., & Sarin, K. Y. (2021). Journal attitudes and outcomes of preprints in dermatology. The British Journal of Dermatology. -
Automated detection of skin reactions in epicutaneous patch testing using machine learning.
Chan, W. H., Srivastava, R., Damaraju, N., Do, H., Burnett, G., MacFarlane, J., … Sarin, K. Y. (2021). Automated detection of skin reactions in epicutaneous patch testing using machine learning. The British Journal of Dermatology. -
Modulation of the Hedgehog signaling pathway in models of basal cell carcinoma by ATP-competitive PKCi inhibitors
Roffey, J., Dillon, C., Oro, A. E., Mirza, A. N., Sarin, K. Y., Aasi, S. Z., … Ator, M. (2018). Modulation of the Hedgehog signaling pathway in models of basal cell carcinoma by ATP-competitive PKCi inhibitors. MOLECULAR CANCER THERAPEUTICS. AMER ASSOC CANCER RESEARCH. -
TGF beta, Fibronectin and Integrin alpha 5 beta 1 Promote Invasion in Basal Cell Carcinoma
Kuonen, F., Surbeck, I., Sarin, K. Y., Dontenwill, M., Ruegg, C., Gilliet, M., … Gaide, O. (2018). TGF beta, Fibronectin and Integrin alpha 5 beta 1 Promote Invasion in Basal Cell Carcinoma. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 138(11), 2432–2442. -
A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations
Pastorino, S., Yoshikawa, Y., Pass, H. I., Emi, M., Nasu, M., Pagano, I., … Carbone, M. (2018). A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations. JOURNAL OF CLINICAL ONCOLOGY, 36(35), 3485-+. -
Automated Classification of Skin Lesions: From Pixels to Practice
Narla, A., Kuprel, B., Sarin, K., Novoa, R., & Ko, J. (2018). Automated Classification of Skin Lesions: From Pixels to Practice. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 138(10), 2108–2110. -
Personal genomics in dermatology: Characteristics of patients who undergo genetic testing for melanoma risk
Fogel, A., & Sarin, K. (2015). Personal genomics in dermatology: Characteristics of patients who undergo genetic testing for melanoma risk. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 72(5), AB99. -
Prevalence of Potentially Allergenic Ingredients in Products Labeled for Eczema Care.
Schwartz, B. L., Honari, G., Chiou, A. S., Ko, J., Sarin, K. Y., & Chen, J. K. (2021). Prevalence of Potentially Allergenic Ingredients in Products Labeled for Eczema Care. Journal of the American Academy of Dermatology. -
Dermatology Advances Into an Era of Precision Medicine.
Wang, J. Y., & Sarin, K. Y. (2021). Dermatology Advances Into an Era of Precision Medicine. JAMA Dermatology. -
Status and Recommendations for Incorporating Biomarkers for Cutaneous Neurofibromas into Clinical Research.
Wallis, D., Stemmer-Rachamimov, A., Adsit, S., Korf, B., Pichard, D., Blakeley, J., & Sarin, K. Y. (2021). Status and Recommendations for Incorporating Biomarkers for Cutaneous Neurofibromas into Clinical Research. Neurology. -
Phase II Open-Label, Single-Arm Trial to Investigate the Efficacy and Safety of Topical Remetinostat Gel in Patients with Basal Cell Carcinoma.
Kilgour, J. M., Shah, A., Urman, N. M., Eichstadt, S., Do, H. N., Bailey, I., … Sarin, K. Y. (2021). Phase II Open-Label, Single-Arm Trial to Investigate the Efficacy and Safety of Topical Remetinostat Gel in Patients with Basal Cell Carcinoma. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Review of the Molecular Genetics of Basal Cell Carcinoma; Inherited Susceptibility, Somatic Mutations, and Targeted Therapeutics.
Kilgour, J. M., Jia, J. L., & Sarin, K. Y. (2021). Review of the Molecular Genetics of Basal Cell Carcinoma; Inherited Susceptibility, Somatic Mutations, and Targeted Therapeutics. Cancers, 13(15). -
Hidradenitis suppurativa in patients of color is associated with increased disease severity and healthcare utilization: A retrospective analysis of 2 U.S. cohorts.
Kilgour, J. M., Li, S., & Sarin, K. Y. (2021). Hidradenitis suppurativa in patients of color is associated with increased disease severity and healthcare utilization: A retrospective analysis of 2 U.S. cohorts. JAAD International, 3, 42–52. -
Transcriptomic Repositioning Analysis Identifies mTOR Inhibitor as Potential Therapy for Epidermolysis Bullosa Simplex.
Lee, G. H., Lekwuttikarn, R., Tafoya, E., Martin, M., Sarin, K. Y., & Teng, J. M. (2021). Transcriptomic Repositioning Analysis Identifies mTOR Inhibitor as Potential Therapy for Epidermolysis Bullosa Simplex. The Journal of Investigative Dermatology. -
Characterization of comorbidity heterogeneity among 13,667 patients with hidradenitis suppurativa.
Hua, V. J., Kilgour, J. M., Cho, H. G., Li, S., & Sarin, K. Y. (2021). Characterization of comorbidity heterogeneity among 13,667 patients with hidradenitis suppurativa. JCI Insight. -
Treatment of Cutaneous Squamous Cell Carcinoma With the Topical Histone Deacetylase Inhibitor Remetinostat.
Kilgour, J. M., Shah, A., Eichstadt, S., Bailey, I., Aasi, S. Z., & Sarin, K. Y. (2021). Treatment of Cutaneous Squamous Cell Carcinoma With the Topical Histone Deacetylase Inhibitor Remetinostat. JAMA Dermatology. -
Development of a Core Outcome Set for Basal Cell Carcinoma (BCC), Including Low-Risk and Advanced Tumors.
Schlessinger, D. I., Reynolds, K. A., Dirr, M. K. A., Ibrahim, S. A., Yanes, A. F., Lazaroff, J. M., … Alam, M. (2022). Development of a Core Outcome Set for Basal Cell Carcinoma (BCC), Including Low-Risk and Advanced Tumors. Journal of the American Academy of Dermatology. -
Partnering with a senior living community to optimize teledermatology via full body skin screening during the COVID-19 pandemic: a pilot program
Trinh, P., Yekrang, K., Phung, M., Pugliese, S., Chang, A. L. S., Bailey, E. E., … Sarin, K. Y. (2022). Partnering with a senior living community to optimize teledermatology via full body skin screening during the COVID-19 pandemic: a pilot program. Skin Health and Disease, 2(3). -
Single-cell analysis of human basal cell carcinoma reveals novel regulators of tumor growth and the tumor microenvironment.
Guerrero-Juarez, C. F., Lee, G. H., Liu, Y., Wang, S., Karikomi, M., Sha, Y., … Atwood, S. X. (2022). Single-cell analysis of human basal cell carcinoma reveals novel regulators of tumor growth and the tumor microenvironment. Science Advances, 8(23), eabm7981. -
Tuberous sclerosis and risk of skin cancer: a nationwide cohort study in the United States.
Trinh, P., Li, S., & Sarin, K. Y. (2022). Tuberous sclerosis and risk of skin cancer: a nationwide cohort study in the United States. Journal of the American Academy of Dermatology. -
ERK2 MAP kinase regulates SUFU binding by multisite phosphorylation of GLI1.
Bardwell, A. J., Wu, B., Sarin, K. Y., Waterman, M. L., Atwood, S. X., & Bardwell, L. (2022). ERK2 MAP kinase regulates SUFU binding by multisite phosphorylation of GLI1. Life Science Alliance, 5(11). -
Neurofibromatosis Type 1 and Risk of Skin Cancer.
Trinh, P., Li, S., & Sarin, K. Y. (2022). Neurofibromatosis Type 1 and Risk of Skin Cancer. JAMA Dermatology. -
Flexible method for generating needle-shaped beams and its application in optical coherence tomography
Zhao, J., Winetraub, Y., Du, L., Vleck, A. V., Ichimura, K., Huang, C., … de la Zerda, A. (2022). Flexible method for generating needle-shaped beams and its application in optical coherence tomography. Optica, 9(8). -
Sociodemographic disparities in patch testing for commercially insured dermatitis patients: a retrospective analysis of administrative claims data.
Qian, M. F., Li, S., Honari, G., Sarin, K. Y., & Chen, J. K. (2022). Sociodemographic disparities in patch testing for commercially insured dermatitis patients: a retrospective analysis of administrative claims data. Journal of the American Academy of Dermatology. -
Assessment of Comorbidities Associated With Allergic Contact Dermatitis in the United States: A Retrospective Claims-Based Study.
Hua, V. J., Li, S., Qian, M. F., Honari, G., Sarin, K. Y., & Chen, J. K. (2022). Assessment of Comorbidities Associated With Allergic Contact Dermatitis in the United States: A Retrospective Claims-Based Study. Dermatitis : Contact, Atopic, Occupational, Drug. -
LY6D marks pre-existing resistant basosquamous tumor subpopulations.
Haensel, D., Gaddam, S., Li, N. Y., Gonzalez, F., Patel, T., Cloutier, J. M., … Oro, A. E. (2022). LY6D marks pre-existing resistant basosquamous tumor subpopulations. Nature Communications, 13(1), 7520. -
Rapid Cellular-Resolution Skin Imaging with Optical Coherence Tomography Using All-Glass Multifocal Metasurfaces.
Zhao, J., Van Vleck, A., Winetraub, Y., Du, L., Han, Y., Aasi, S., … de la Zerda, A. (2023). Rapid Cellular-Resolution Skin Imaging with Optical Coherence Tomography Using All-Glass Multifocal Metasurfaces. ACS Nano. -
Prevalence of allergic contact dermatitis following patch testing in patients with atopic dermatitis: a retrospective United States claims-based study.
Qian, M. F., Li, S., Honari, G., Sarin, K. Y., & Chen, J. K. (2023). Prevalence of allergic contact dermatitis following patch testing in patients with atopic dermatitis: a retrospective United States claims-based study. Journal of the American Academy of Dermatology. -
Development of a novel MEK inhibitor, NFX-179, as a chemoprevention agent for squamous cell carcinoma.
Sarin, K. Y., Kincaid, J., Sell, B., Shahryari, J., Duncton, M. A. J., Morefield, E., … Tsai, K. Y. (2022). Development of a novel MEK inhibitor, NFX-179, as a chemoprevention agent for squamous cell carcinoma. CANCER PREVENTION RESEARCH. AMER ASSOC CANCER RESEARCH. -
Development of a novel MEK inhibitor, NFX-179, as a chemoprevention agent for squamous cell carcinoma
Sarin, K. Y., Kincaid, J., Sell, B., Shahryari, J., Duncton, M. A. J., Morefield, E., … Tsai, K. Y. (2022). Development of a novel MEK inhibitor, NFX-179, as a chemoprevention agent for squamous cell carcinoma. CANCER PREVENTION RESEARCH. AMER ASSOC CANCER RESEARCH. -
Modulation of Inflammatory Proteins in Serum May Reflect Cutaneous Immune Responses in Cancer Immunotherapy.
Han, J., Correa da Rosa, J., Agarwal, A., Owji, S., Yassky, D., Luu, Y., … Gulati, N. (2023). Modulation of Inflammatory Proteins in Serum May Reflect Cutaneous Immune Responses in Cancer Immunotherapy. JID Innovations : Skin Science from Molecules to Population Health, 3(2), 100179. -
Sociodemographic disparities in patch testing for commercially insured patients with dermatitis: A retrospective analysis of administrative claims data
Qian, M. F., Li, S., Honari, G., Sarin, K. Y., & Chen, J. K. (2022). Sociodemographic disparities in patch testing for commercially insured patients with dermatitis: A retrospective analysis of administrative claims data. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 87(6), 1411–1413. -
The type 1 interferon signature reflects multiple phenotypic and activity measures in dermatomyositis.
Tabata, M. M., Hodgkinson, L. M., Wu, T. T., Li, S., Huard, C., Zhao, S., … Fiorentino, D. (2023). The type 1 interferon signature reflects multiple phenotypic and activity measures in dermatomyositis. Arthritis & Rheumatology (Hoboken, N.J.). -
cNF-Skindex in adults living with Neurofibromatosis 1: severity strata in France and validation in US adults.
Fertitta, L., Sarin, K. Y., Bergqvist, C., Patel, E., Peiffer, B., Moryousef, S., … Wolkenstein, P. (2023). cNF-Skindex in adults living with Neurofibromatosis 1: severity strata in France and validation in US adults. The Journal of Investigative Dermatology. -
Association of multiple primary melanomas with malignancy risk: A population-based analysis of entries from the Surveillance, Epidemiology, and End Results program database during 1973-2014
Cai, E. D., Swetter, S. M., & Sarin, K. Y. (2023). Association of multiple primary melanomas with malignancy risk: A population-based analysis of entries from the Surveillance, Epidemiology, and End Results program database during 1973-2014. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 88(5), e211–e219. -
RAS Signaling Gone Awry in the Skin: The Complex Role of RAS in Cutaneous Neurofibroma Pathogenesis, Emerging Biological Insights.
Rhodes, S. D., McCormick, F., Cagan, R. L., Bakker, A., Staedtke, V., Ly, I., … Sarin, K. Y. (2023). RAS Signaling Gone Awry in the Skin: The Complex Role of RAS in Cutaneous Neurofibroma Pathogenesis, Emerging Biological Insights. The Journal of Investigative Dermatology. -
Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.
Cannon, A., Sarin, K. Y., Petersen, A. K., Pichard, D. C., Wolters, P. L., Erickson, G., … Plotkin, S. R. (2023). Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials. Clinical Trials (London, England), 17407745231178839. -
Hidradenitis suppurativa and Ehlers-Danlos syndrome: A case-control study.
Hua, V. J., Li, S., Sarin, K. Y., & Aleshin, M. (2023). Hidradenitis suppurativa and Ehlers-Danlos syndrome: A case-control study. JAAD International, 12, 70–71. -
Advances in cutaneous squamous cell carcinoma.
Winge, M. C., Kellman, L. N., Guo, K., Tang, J. Y., Swetter, S. M., Aasi, S. Z., … Khavari, P. A. (2023). Advances in cutaneous squamous cell carcinoma. Nature Reviews. Cancer. -
Flexible method for generating needle-shaped beams and its application in optical coherence tomography.
Zhao, J., Winetraub, Y., DU, L., VAN Vleck, A., Ichimura, K., Huang, C., … DE LA Zerda, A. (2022). Flexible method for generating needle-shaped beams and its application in optical coherence tomography. Optica, 9(8), 859–867. -
A Call for Discovery and Therapeutic Development for Cutaneous Neurofibromas.
Blakeley, J. O., Le, L. Q., Lee, S. Y., Ly, I., Rhodes, S. D., Romo, C. G., … Wolkenstein, P. (2023). A Call for Discovery and Therapeutic Development for Cutaneous Neurofibromas. The Journal of Investigative Dermatology. -
Cross-comparison of inflammatory skin disease transcriptomics identifies PTEN as a pathogenic disease classifier in cutaneous lupus erythematosus.
Aevermann, B. D., Di Domizio, J., Olah, P., Saidoune, F., Armstrong, J. M., Bachelez, H., … Gilliet, M. (2023). Cross-comparison of inflammatory skin disease transcriptomics identifies PTEN as a pathogenic disease classifier in cutaneous lupus erythematosus. The Journal of Investigative Dermatology. -
Development of a digital tool for home-based monitoring of skin disease for older adults.
van Egmond, S., Cai, Z. R., Nava, V., Joy de Vere Hunt, I., Rapaport, B. R., Ko, J., … Linos, E. (2023). Development of a digital tool for home-based monitoring of skin disease for older adults. Skin Health and Disease, 3(5), e235. -
Development of a MEK inhibitor, NFX-179, as a chemoprevention agent for squamous cell carcinoma.
Sarin, K. Y., Kincaid, J., Sell, B., Shahryari, J., Duncton, M. A., Morefield, E., … Tsai, K. Y. (2023). Development of a MEK inhibitor, NFX-179, as a chemoprevention agent for squamous cell carcinoma. Science Translational Medicine, 15(717), eade1844. -
A core outcome domain set to assess cutaneous neurofibromas related to neurofibromatosis type 1 in clinical trials.
Fertitta, L., Bergqvist, C., Sarin, K., Plotkin, S. R., Moertel, C., Petersen, A. J., … Wolkenstein, P. (2023). A core outcome domain set to assess cutaneous neurofibromas related to neurofibromatosis type 1 in clinical trials. The British Journal of Dermatology. -
Toward risk stratification and personalized therapy for neurofibromas in neurofibromatosis type 1.
Romo, C. G., Sarin, K. Y., & Blakeley, J. O. (2023). Toward risk stratification and personalized therapy for neurofibromas in neurofibromatosis type 1. The British Journal of Dermatology. -
Impaired innate and adaptive immune responses to BNT162b2 SARS-CoV-2 vaccination in systemic lupus erythematosus.
Sarin, K. Y., Zheng, H., Chaichian, Y., Arunachalam, P. S., Swaminathan, G., Eschholz, A., … Zaba, L. C. (2024). Impaired innate and adaptive immune responses to BNT162b2 SARS-CoV-2 vaccination in systemic lupus erythematosus. JCI Insight, 9(5). -
Noninvasive virtual biopsy using micro-registered optical coherence tomography (OCT) in human subjects.
Winetraub, Y., Van Vleck, A., Yuan, E., Terem, I., Zhao, J., Yu, C., … de la Zerda, A. (2024). Noninvasive virtual biopsy using micro-registered optical coherence tomography (OCT) in human subjects. Science Advances, 10(15), eadi5794. -
Filling the Prescription Gap: The Value of Community Support in Psoriasis Management.
Leeolou, M. C., Sarin, K. Y., & Fiorentino, D. F. (2024). Filling the Prescription Gap: The Value of Community Support in Psoriasis Management. The British Journal of Dermatology. -
Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1.
Sarin, K. Y., Bradshaw, M., O'Mara, C., Shahryari, J., Kincaid, J., Kempers, S., … Le, L. Q. (2024). Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1. Science Advances, 10(18), eadk4946. -
Parental E-Cigarette Use and Pediatric Atopic Dermatitis.
Youn, G. M., Sarin, K. Y., Chiou, A. S., Chen, J. K., & Honari, G. (2024). Parental E-Cigarette Use and Pediatric Atopic Dermatitis. JAMA Dermatology. -
Analysing common topics of secure patient messages in hidradenitis suppurativa: a text-embedding and natural language-processing approach.
Chen, M. L., Kim, J., Naik, H. B., Aleshin, M. A., Sarin, K. Y., Barnes, L. A., & Linos, E. (2024). Analysing common topics of secure patient messages in hidradenitis suppurativa: a text-embedding and natural language-processing approach. The British Journal of Dermatology. -
Germline BARD1 variants predispose to mesothelioma by impairing DNA repair and calcium signaling.
Novelli, F., Yoshikawa, Y., Vitto, V. A., Modesti, L., Minaai, M., Pastorino, S., … Carbone, M. (2024). Germline BARD1 variants predispose to mesothelioma by impairing DNA repair and calcium signaling. Proceedings of the National Academy of Sciences of the United States of America, 121(29), e2405231121. -
Unveiling the genetic landscape of hereditary melanoma: From susceptibility to surveillance.
Zheng, C., & Sarin, K. Y. (2024). Unveiling the genetic landscape of hereditary melanoma: From susceptibility to surveillance. Cancer Treatment and Research Communications, 40, 100837. -
Cutaneous Neurofibromas and Quality of Life in Adults With Neurofibromatosis Type 1.
Lin, M. J., Yao, H., Vera, K., Patel, E., Johnson, M., Caroline, P., … Sarin, K. Y. (2024). Cutaneous Neurofibromas and Quality of Life in Adults With Neurofibromatosis Type 1. JAMA Dermatology. -
TLR7/8 Activation in Immune Cells and Muscle by RNA-Containing Immune Complexes: Role in Inflammation and the Pathogenesis of Myositis.
Wu, Y., Deshpande, A., Geraci, N., Budde, P., Sellers, V., Velisetty, P., … Bender, A. T. (2024). TLR7/8 Activation in Immune Cells and Muscle by RNA-Containing Immune Complexes: Role in Inflammation and the Pathogenesis of Myositis. Arthritis & Rheumatology (Hoboken, N.J.). -
Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis.
Starrett, G. J., Baikie, B. C., Stoff, B. K., Grossniklaus, H. E., Van Buren, I., Berry, E. G., … Sargen, M. R. (2024). Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, OF1–OF13. -
Toll-Like Receptor 7/8 Activation of Immune and Non-Immune Cells in Muscle by RNA-Containing Immune Complexes Can Contribute to Inflammation and the Pathogenesis of Myositis
Wu, Y., Deshpande, A., Geraci, N., Sellers, V., Velisetty, P., Fiorentino, D., … Bender, A. (2023). Toll-Like Receptor 7/8 Activation of Immune and Non-Immune Cells in Muscle by RNA-Containing Immune Complexes Can Contribute to Inflammation and the Pathogenesis of Myositis. ARTHRITIS & RHEUMATOLOGY. WILEY.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Practice Locations
General Dermatology Clinic in Portola Valley Portola Valley, CA
Portola Valley, CA
General Dermatology Clinic in Portola Valley
3240 Alpine Road
Portola Valley , CA 94028
Make An Appointment More Clinic Information Getting HereSkin Cancer Program in Palo Alto Palo Alto, CA
Palo Alto, CA
Skin Cancer Program in Palo Alto
900 Blake Wilbur Drive, 3rd Floor
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereStanford Pigmented Lesion and Melanoma Program at Stanford Cancer Center Palo Alto Palo Alto, CA
Palo Alto, CA
Stanford Pigmented Lesion and Melanoma Program at Stanford Cancer Center Palo Alto
900 Blake Wilbur Drive, 3rd Floor
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(265 reviews)
Kavita Sarin is an extremely thorough doctor who listens very carefully and follows through. I feel she is very competent and a great asset to Stanford. She is one of the best doctors I have ever had.
Careful exam, polite people.
Greeting was good at the frint desk, Oscar cheerful and positive dr. Sarin excellent
She is one of the best and most competent dermatologists I have met over 30 years. She is highly focused on the patient and is using leading edge medications that are transformative.
courteous and informative
Above reproach. Exceptional in every way.
Thank you!
Dr. satin is exceptional.
always exceptional
Professional, efficient, knowledgeable, and friendly
I would be very likely to recommend my Dr Kavita Sarin
She’s Extremely intelligent Dr. Her knowledge depicts that she’s doing a great job to help the people with different dermatology problems. Her studies are proving to be positive with time she can achieve the un achievable.
Excellent
Dr.Sarin and her associate were very patient with good explanations for me on my skin markings.
Dr. Sarin is excellent! Great person, Great doctor!
very thorough ! and. informative
Dr. Sarin was courteous and personable, a good listener and responder, thorough and patient. I was totally satisfied with this consultation, and grateful that she and her staff fit me into a cancellation on very short notice.
Dr. Sarin was very clear made me feel at ease
Outstanding!
Very quick and complete
Excellent, highest quality of service for her patients.
Attentive and supportive
Friendly, efficient, informative, and helpful!! I feel good about the next steps we identified and discussed.
excellent grade inn bedside manners, communication and scheduling
Excellent all aspects: knowledge fund; competence; integrity; manner/compassion; diligence
The doctor was 25 minutes late but accommodated the fact I had to go pick up my kid and contacted me later
Overall very good experience
Dr. Sarin has wonderful bedside manner
Superb. Dr. Sarin is excellent.
Dr.Sari is fantastic and her resident was great
My complete confidence in Dr. Sarin
Dr Sarin is an exceptional doctor
Excellent, listens to patient and recommends options.
All the staff and doctors were very pleasant. No waiting
Dr. Sarin is in all ways terrific.
She took her time and was thorough.
Dr Sarin is excellent
Dr. Sarin has a calm and patient manner.
Dr Sarin is the best provider I've seen at Stanford!
on time, very thorough. love her!
Incredible compassionate health care at its finest. All my questions answered.
she's outstanding.
Kavita Saren is excellent
Excellent all around
Dr Sarin is fantastic: smart,. Caring, and gentle!
Excellent Dr. and Resident
Dr Sarin and her team are exceptional care providers
As usual Dr. Sarin was excellent and the knowledge and professionalism Dr. Hinton exhibited during the exam and procedure she performed made me quite comfortable during this visit.
Clean facility, Friendly staff, and knowledgeable doctors.
Love Dr. Sarin and she always has nice residents
She's personable and explains things well. I feel I can ask her questions without any hesitation. She went over several options for my treatment and helped me decide on the best one for me. Her resident, Christina (Lin? Lind?) was also very helpful and responsive,.
Dr. Sarin and team are trustworthy and knowledgeable
Very good appointment.
Dr. Sarin is wonderful!
great doctor, excellent service
Both Dr. Sarin and her resident were excellent!
Outstanding!
Exceptional is the word for Dr Sarin and her team.
Very nice and successful visit
She is very helpful
Dr Sarin is always fabulous!
Dr Sarin is very friendly and patient for my questions.
She is an exceptional doctor: caring, super competent and I appreciate being able to see her on video given I live out of area
Always great.. professional, personable, individualizes care
Dr. Sarin is wonderful. I am a physician and refer many patients to her as well as see her myself!
Exceptionally skilled Doctor and assistant with excellent communication skills.
Superb doctor
Awesome doctor & awesome resident I will refer everyone I know :)
Dr Sarin and crew are caring, experienced and efficient.
Kavita is amazing. She’s smart, approachable, caring and professional. I’m so lucky that she’s my doctor
My doctor and all the staff were fantastic. They took the time to explain everything and to make sure I understood.
Both Drs.Rieger and Sarin are outstanding. I have complete confidence in their concern for my health,
Superb, comprehensive, warm, professional,, quick care
Gotta love Dr Sarin!
Dr. Sarin is the best!!!
Dr Sarin is so knowledgeable and also very upbeat. I also enjoyed meeting Dr. Miller (the resident) who was helpful and caring.
Dr. Kavita Sarin is exceptional. Staff are excellent.
Always very thorough. Personable and well explained treatment.
Dr Sarin was, as always, thoughtful and considerate of my needs as a patient. The resident intern likewise was professional and attentive
she spent a lot of time with me , very details and informative!
Dr Sarin is the best! She gets to know her patients and is always willing to hrlp
Dr Sarin is a great doctor
Dr Sarin is terrific.
Dr. Sarin is an excellent physician who is very thorough and comprehensive in explaining my medical issues to me. I
Kind, considerate, professional care.
Dr Sarin and her resident were terrific
Dr Sarin is competent and attentive to her patients' care issues
Excellent complete overview of my issues
Everyone was so helpful! From the check in process and follow up from dr Sarin
It was exceptional all the staff were professional.
Dr. Sarin is fantastic -- I trust her completely.
Excellent medical care!
Dr Sarin is awesome! She listens and is spot on!
Drs. Sarin and Miller were kind, professional, thorough and thoughtful. I am totally satisfied with this visit.
Excellent in all aspects.
Highly recommend Dr. Sarin. FYI: This is a badly worded question.
Dr. Sarin is always a complete pleasure to deal with; professional, extremely competent, and takes the time to make sure all my questions are answered.
I like Dr. Sarin. A lot. If I didn't, I wouldn't go to Portola Valley from Redwood City to see her for in-person visits. I would pick a dermatologist with offices in Redwood City.
fantastic visit and doctors
Dr. Sarin is thorough and pleasant
Dr. Sarin is a very good listener. Her kindness and caring were shown through out our visits and interaction over the past two years. So grateful for her care.
Seems very knowledgeable and friendly
I wish more physicians were like Kavita. This was truly exceptional. She was thoughtful - no cookie cutter diagnoses - she spent time understanding the problem and worked on a smart, efficient solution with me. She was warm and interested in my case, and knowledgeable, yet also considered my ideas and thoughts authentically.
Outstanding. I’ve had several not great experiences with caregivers at Stanford recently, so this one really stood out.
Excellent
Dr. Yang is perfect in every way! Her residents are always perfect as well!
Top the line. Get a resident plus world expert.
Dr Sarin is an amazing doctor and gave me all of my options. She walked through all the details.
Thank you for the prompt service. You made it very easy! And it was amazing to have the appointment start right on time!
Dr. Sarin is terrific
Dr. Sarin is an excellent physician! Informative, helpful, friendly, kind, and answered all of my questions. Superb.
Dr Sarin is a smart, through, and caring physician. I felt she was genuinely interested in solving my problem. Highly recommended.
Dr. Sarin is knowledgeable and a really nice person. Her residents have been uniformly friendly, knowledgeable and helpful. What a great practice this is!
Kavita was excellent.
I recommended Dr. Sarin to all of my relatives.
THE BEST
five stars. I switched from another dermatologist to Dr. Sarin a few years ago, and I am so glad I did.
The care from the providers is excellent. The scheduling system and availability are terrible.
She was very helpful as to what might be causing my sudden hair loss.
Dr Sarin is an exceptional practitioner - caring, explaining pathologies and remedies, thorough
Loved her patience with all my queries and she addressed all of them and gave recommendations and background knowledge on the cause of the issue.
She seemed intelligent and pleasant. The visit was brief, but she was responsive to my needs, and we will meet in person sometime in the next little while.
Dr. Sarin is excellent in every way.
Dr. Sarin is very upbeat and thorough!
The doctor was very friendly and professional.
Perfect experience glad that it could be in person -
Dr. Sarin is fantastic. I was impressed with her - like my other drs. at SUMC - because she treats me (an octogenarian) as a PERSON & does not write me off as just an old biddy.
Dr Sarin is spectacularly efficient, smart, and straightforward.
Dr. Sarin was warm, friendly and engaging. I have no complaints about her. She was Covid appropriate. I would highly recommend her.
Excellent physician
Dr Sarin is excellent - very thorough, professional, and friendly. She takes time to discuss my health problem with my and why she's doing the procedures she's doing. I feel she's interested in my health.
She's the best!
I drove all the way from Modesto to Portola Valley just to see Dr. Sarin. She is outstanding in her field. She has a very positive demeanor and wonderful feeling tone. Very knowledgeable in her area! (Dermatology.)
As always, Dr. Sarin is an outstanding physician, caring with an excellent skills as a physician
Dr. Sarin is excellent.
Dr. Sarin is fantastic.. Her student Dr. Tu was excellent.
Consistently professional.
Dr. Sarvin is caring, efficient, knowledgeable.
Dr Sarin always explains everything clearly. She remembers medical and non-medical topics we've discussed in the past (which I find amazing, given the number of patients she deals with). Excellent bedside manner!
Dr. Sarin was courteous, friendly, professional, and thorough. I felt she was genuinely interested in me and my concerns. I would recommend her to any new patient.
Good experience.
Dr. Sarin is very thoughtful and responds to our concerns. She is also very thorough.
Dr. Sarin is fantastic
Dr. Sarin is amazing.
Not as thorough as past experience with other providers.
love Dr. Sarin and feel blessed to be in her care. Thank you so much!
Dr. Sarin is awesome!
good bedside mannerswelcoming
Dr. Sarin was very good in diagnosing my skin condition, and she gave me very good treatment recommendations
She has very good bedside manners. She is also very informative with my issues. Learn something new that the other doctors never mention. Wish she practice closer to my location. I was very happy with the care she has given me that day.
Dr. Sarin is excellent. She put me at ease, very patient, kind, upbeat, professional and thorough.
Exceptional experience
Dr Kavita is the best dermatologist on the Face ID the earth . She has detected many issues with my skin and always have the right solution.
Dr Sarin is thoughtful in terms of my care, she's smart, compassionate and spends lots of time with me
Dr Sarin is a great doctor. I've seen her a few times and she is always pleasant, knowledgeable and does a great job.
Dr. Sarin was wonderful!
dr sarin is fabulous. she greets you like she is seeing her best friend
My overall experience was excellent. Dr. Sarin is a fantastic doctor!
Both, the Resident and the Attending were great, friendly and explained well my problem and options. Great service!
Dr. Sarin is outstanding
Dr. Sarin has the extraordinary gift of masterful use of clearly-articulated discourse to illuminate for the patient a complex network of connections between symptoms and potential causes, unveiling in a very friendly and easily-comprehensible manner her medical reasoning from premise to conclusion, and thus providing the patient with a clear understanding of the situation, crystal-clear explanation of plan of assessment and treatment, and precise instructions for after-visit care. I have rarely met a medical professional with such an outstanding capacity to communicate clearly and to the point all the relevant information, while also listening and pertinently responding to questions.
Dr Sarin is a bright light in medicine.
Dr. Sarin is an incredible talent & personality.
Dr. Sarin is outstanding.
Dr Sarin is amazing. Patient, kind, works with me as a team
I have passed on the good service this dept. provides. Many people from the Sequoias already attend here.
Answers questions caring attitude.
I am very happy and confident with my care provider! I highly recommend her with my friends and family!!
While she told me that the condition I have and the treatments necessary were not something she could treat, she gave me information and follow up info for someone who might be able to help.
Good.
dr Sarin is an incredibly fine physician. thank you.
Dr Sarin was as professional and empathetic as she3 could be1
Dr Sarin is great!
my providers are awesome and true professionals
Excellent doctor. Dr. Sarin is wonderful, very very good.
Outstanding!
Fantastic Doctor Dr Kavita
Dr.Sarin is a GREAT Doc - I am fortunate to have her as my dermatologist
Dr. Sarin is the best dermatologist I have been to. And I have 30 years of derm visits! She is wonderful.
Kavita is amazing. She's got great energy and always has a big smile! I love the way she works with you to figure out the best path in a collaborative method. The best doctor I've ever worked with!
I felt very well considered and cared for. Even got to listen to Classical music during my surgery. They were both really great and accommodating, answering questions, letting me take a look at the mass they removed when I asked, and really making sure everything went well. Really excellent care, which is to be expected with Stanford!
Dr. Kavita Sarin is an outstanding dermatologist. I am convinced of her competence. She exudes knowledge and shares it freely and with kindness. She is so professional and up to date on the minutest details of her profession. She can explain things on the microbiology level to the huge picture so well. She was referred to me as a superb physician by an outstanding dermatologist who we had under our PPO and there is no doubt she exceeds the referral if that is possible! I am very grateful to be under her care for my dermatology needs.
They are always wonderful.
Dr. Sarin is a perfect combination of friendly-but-efficient and knowledgeable-but-concise. And also thorough in reviewing notes and issues from previous visits.
Dr Sarin addressed my concerns in great detail and I left the clinic feeling empowered about the information she gave me from her exam
Dr Sarin is excellent! Patient with me, calm, passionate, and make correct diagnosis! I'm lucky to have her as my doctor
Overall, it was good but nothing special. The doctor took time to answer all my questions and this was important but left as soon as she finished answering and I was left alone in the room wondering what I was supposed to do next! So, I changed and went back to the front desk by myself --- felt a bit strange.
Dr. Sarin is fantastic. She is very professional,kind and caring. I'm delighted I've found a dermatologist I am totally confident in and look forward to my next check up!
Dr. Sarin is highly personable and attentive. What a gem! I very much appreciate her service.
Dr. Sarin is the VERY BEST!!!
Dr. Sarin provided me with excellent care. she addressed every skin condition I was concerned about and treated them right then and there. I raved about Dr. Sarin to my husband and I'm hoping that they will accept him as a new patient as well. She is lovely, very personable, caring and extremely efficient.
Dr. Sarin is very nice, professional & knowledgeable. She is also very patient with me. Very good doctor. Already recommend her to other friends.
Dr. Sarin is great. She has a 10+ of knowledge in her field and has good suggestions. Very good at explaining new options for medicine too.
It was far and she was great. Wish I'd qualified for the clinical trial, but it isn't her fault my condition decided to go into remission, heh!
They are awesome.
Dr. Sarin has a very caring manner. She is an extremely pleasant person.
Dr. Sarin was friendly, clear, professional and empathetic. I was impressed with both her and the intern and how they worked together! thank you Dr. Sarin.
Dr Sarin is a superb doctor.
Dr Sarin is extremely knowledge. She is caring and has great bedside manner. I cannot ask for any better doctor.
Dr. Sarin is one of the best doctors I have ever had.
Dr Sarin is great
I have no complaint all was very good.
Once I got to see Dr. Sarin, she was terrific.
I love the way things are done here
Dr. Sarin exuded confidence so I was reassured from the beginning that my problems would be resolved as well as possible. She was efficient, friendly - just what a patient wants in a care provider.
No concerns. Everything went smoothy with great communication.
Detailed and helpful
Dr Sarin is a great listener, shows genuine concern, and is open to patient input
Dr. Sarin & her resident are excellent.
Dr. Sarin is a superb doctor I could not ask for a better dermatologist.
The doctors are courteous, patient and very professional. At no point did I feel discomfort to discuss any issues or ask questions. We discussed several medications and I was able to make a decision on what seemed right for me. I definitely recommend the Portola clinic to anyone.
My one comment about Dr. Sarin is that she speaks very fast. She is very confident and competent, but it was a great deal of new information and vocabulary for me (a well-educated patient), so it was difficult for me to understand and follow her.
As usual utmost professionalism applied.
Dr. Sarin was very good and very knowledgeable. My only observation is that she talks a little too quickly, making it a little difficult to follow her, especially when medical terminology is used.
very good over all experience
excellent dermatologist
dr was amazing
Most Drs are pretty bright. Dr Sarin is VERY bright. As a research scientist she is on top of the latest developments in the field. I've seen her twice, both times she's asked if I have questions on anything and then spent the time to fully explain the answer.
Dr Sarin is the best.
Doctor & assistant were the best.
Dr. Sarin was superb!
Dr. Sarin is the "best of the best."
It was worth waiting two months to see her.
I understood some/many of the dermatology vocabulary. Dr. Sheu & Sarin were not "rushing out the door' and provided time to answer my questions. Dr. Sheu was patient and Dr. Sarin also provided time.
I felt heard and cared for. Dr. Sarin did not seem in any rush to get me in and out. She focused on me.
Dr. Sarin is wonderful, very wonderful.
Dr. Sarin was excellent, listened to all of my concerns, took the time to explain everything to me, and let me make informed decisions about medication options. I've already recommended Dr. Sarin to colleagues.
Dr. Sarin and Resident Dr. Sarah were both wonderful. I can't say enough about these two splendid people.
I was impressed that Dr. Sarin did not rush the appointment. She was very thorough.
I have recommended Dr. Sarin to others!
it would be helpful for the Care provider to use words that the patient could understand.
Such incredible, high quality dermatologist!
I did recommend her
She is very, very nice!
Dr. Savin very knowledgeable and explained well my treatment options. We together chose one treatment that best fit my situation and what I was willing to do.
The doctor and I were both prepared for the appointment because of correspondence using the app!
positive
Very thorough job with special emphasis on my issues. Super job.
Excellent Clinician
Dr. Sarin is exceptional. She seems extremely intelligent and has a wonderful manner.
Care provider was knowledgeable and kind but very late.
Wonderful care and concern!
Dr. Sarin was very helpful and clear.
Again, Dr. Sarin the best ! Already referred two people to her and they too are very happy.
Very capable and knowledgeable. I am very enthusiastic about this doctor.
Appreciate dr sarin!
During this visit I had two biopsies. The results of these biopsies from the lab doctor were totally over my head. I had to ask the doctor what was meant. She told me in simple terms. "No problem."
Dr. Sarin is outstanding
Was not specific about medications recommended, information she said she was going to give or follow-up instructions.
she seemed rushed otherwise very nice and very educated
Responsive, caring, A#1,
We have recommended Dr. Sarin to others in our community.
Dr. Sarin exemplifies true professionalism - knowledge, communication & personality!
Excellent and very knowledgeable.
The student intern provided an assessment then the dermatologist came in to discuss and review the assessment.
Dr. Sarin is personable and completely professional.
Very good. I look forward to seeing Dr. Sarin again.
I felt very well taken care of.
I having V good experience.
Care provider shows a really caring attitude toward her patient.
Very good experience.
Dr. Sarin provided a very knowledgeable diagnosis; thorough guidance.
Dr. especially helpful, informative.
I am more than satisfied with the care provided by Dr. Sarin.
Dr. Kavita Sarin is excellent!
Would like a complete, in-depth explanation of condition and causes, not just need to know treatment. Holistic treatment options (e.g., diet changes, exercise) should be discussed in addition to traditional western medicine.
Did not seem to understand my needs. At the end of the appointment she realized I actually needed to seen an allergy specialist.
View More
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records